Abstracts tagged "Therapy, alternative"

Abstract Number: 1599 • ACR Convergence 2025
Cyclophosphamide versus Rituximab in the treatment of Anca-associated Vasculitis: Adverse events and Relapses
Fabricio Benavides Villanueva¹, Diana Prieto-Peña², Vanesa Calvo-Río³, Monica Renuncio-García⁴, Adrian Martin-Gutierrez⁵, Amparo Sanchez-Lopez⁶, Claudia Poo-fernandez⁷, maria Rodríguez-Vidriales⁸ and Ricardo Blanco³, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ³Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁶Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁷Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). EGPA presents a different pathogenic,…
Abstract Number: 0207 • ACR Convergence 2025
The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)
Suzi Hong¹, Marcos Monteon², Kathleen Bundy³, Chloe Delgado Ramirez³, Phoebe Senowitz³, Monica Guma⁴, Nina Acebo⁵, Chris Pruitt⁶, Tanya Shekhtman³, Shahrokh Golshan⁷ and Susan Lee⁸, ¹Herbert Wertheim School of Public Health and Human Longevity Science UCSD; Department of Psychiatry UCSD, San Diego, ²University of California, San Diego, San Diego, ³Department of Family Medicine, Center for Integrative Health, Krupp Endowment Fund, UCSD, La Jolla, ⁴University of California San Diego, San Diego, CA, ⁵University of California, San Diego, La Jolla, ⁶Herbert Wertheim School of Public Health and Human Longevity Science, UCSD, La Jolla, ⁷Department of Pyschiatry, UCSD, La Jolla, ⁸Department of Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: There have been over 777 million cases of acute COVID-19 infections worldwide as of April 2025. Although many patients recover, an estimated 10-30% of…
Abstract Number: 1550 • ACR Convergence 2025
Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Virginia Carrizo Abarza¹, Qixuan Li², Teresa Semalulu³, Justin Smith³, Pankti Mehta⁴, Fadi Kharouf⁵, Dafna D. Gladman⁶, Laura Whitall Garcia⁷ and Zahi Touma³, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1), blocking interferon activity and reducing disease activity in…
Abstract Number: 0096 • ACR Convergence 2025
GLUT1-Dependent Targeting and Enhanced Selectivity of a Glucose-Methotrexate Conjugate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Sebastian Makuch¹, Jacek Polański¹ and Wojciech Tański², ¹Wrocław Medical University, Wrocław, Poland, ²Wrocław University of Science and Technology, Wrocław, Poland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease where fibroblast-like synoviocytes (FLS) play a central role in joint inflammation and destruction. Methotrexate (MTX), a…
Abstract Number: 1346 • ACR Convergence 2025
Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
YU Chen¹, Chien-Sheng Wu², Jacob Shujui Hsu³ and Pei-Lung Chen⁴, ¹Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C. Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., New Taipei City, Taiwan (Republic of China), ²Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C., New Taipei city, Taiwan (Republic of China), ³Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei city, Taiwan (Republic of China), ⁴Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei, Taiwan (Republic of China)
Background/Purpose: Multiple Single-Nucleotide Polymorphisms (SNPs), including those in the methotrexate and azathioprine metabolic pathways, are associated with poor response to conventional disease-modifying anti-rheumatic drugs (cDMARDs)…
Abstract Number: 0056 • ACR Convergence 2025
Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model
Maripat Corr¹, Grace Hsueh², Aaron place², David Lucas² and NANCY LANE³, ¹ucsd, San Diego, CA, ²ANI Pharmaceuticals, Inc., Baudette, MN, ³University of California at Davis, School of Medicine, Sacramento, CA
Background/Purpose: Melanocortin receptor agonists, such as adrenocorticotropic hormone (ACTH), are anti-inflammatory with pleotropic functions. We aimed to evaluate the effects of a repository corticotropin injection…
Abstract Number: 1297 • ACR Convergence 2025
Biologic Therapy for Refractory Juvenile Scleroderma: a retrospective case-series from a single tertiary care center in Saudi Arabia.
MUNIRA ALMARRI, Deena Alwakeel, Abdulaziz Alrowais and Abdulrahman Asiri, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Background/Purpose: Scleroderma is autoimmune disease that may result in changes to the skin, blood vessels, muscles, and internal organs. It can be either Localized Scleroderma…
Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
Abstract Number: 1246 • ACR Convergence 2025
Myo Vs. Myo-fascial Injection for Myofascial Trigger Points. Is There Really a Difference? A Randomized Controlled Trial
seda yildiz¹, bugra ince¹ and Halil ibrahim candal², ¹izmir sehir hastanesi, izmir, Turkey, ²ızmir sehir hastanesi, izmir
Background/Purpose: Experimental and clinical studies suggest that fascial structures play a critical role in the pathogenesis and pain mechanisms of myofascial pain syndrome (MTrP). It…
Abstract Number: 0584 • ACR Convergence 2025
Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
Rodrigo García Salinas¹, Nataly Mejia², Santiago Ruta³ and Sebastian Magri⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital San Martin de La Plata, La Plata, Argentina, ⁴Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The concept of difficult-to-Manage axial spondyloarthritis (axSpA D2M), recently introduced by ASAS, describes patients who fail ≥2 lines of b-tsDMARDs treatment and remain active…
Abstract Number: 1158 • ACR Convergence 2025
Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Guishan Liu¹, Jingyuan zhang², jin Xu², JiaYuan Dai² and Min Shen², ¹Peking union medical college hospital, Beijing, Beijing, China (People's Republic), ²Peking union medical college hospital, Beijing, China (People's Republic)
Background/Purpose: Heterozygous loss-of-function mutations in CTLA4 cause a spectrum of immune dysregulation, characterized by hypogammaglobulinemia, autoimmune cytopenias, and lymphoproliferation, yet penetrance and expressivity remain highly…
Abstract Number: 0582 • ACR Convergence 2025
Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Prabhu Vasantha Kumar¹, John Mathew², Ashish Jacob Mathew³ and Ruchika Goel², ¹Christian Medical College, Vellore, Tamil Nadu, India, Vellore, Tamil Nadu, India, ²Christian Medical College, Vellore, Tamil Nadu, India, ³Christian Medical College, Vellore, India
Background/Purpose: Despite the good efficacy of bDMARDs in nearly 60% of patients with axial spondyloarthritis (AxSpA), high costs limit their use in resource-limited settings. Few…
Abstract Number: 1021 • ACR Convergence 2025
Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cannabis use has increased substantially in the general population over the past decade, driven by changing legal landscapes and expanding public interest in its…
Abstract Number: PP07 • ACR Convergence 2025
Beyond the Medication: Creating a Toolbox of Complementary Therapies
Brittany Murray
Background/Purpose: For over 30 years, I have been living with Psoriatic Disease, diagnosed with Psoriasis at 2 years old and Psoriatic Arthritis at 14. My…
Abstract Number: 0942 • ACR Convergence 2025
Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus
Jennifer Nicholson¹, Maria Ossa-Echeverri¹, Arpitha Haranahalli Shivarudrappa¹, Mark Lusco¹, Maria de la Luz Garcia-Hernandez², John Looney¹, Jennifer Anolik³ and Javier Rangel-Moreno¹, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Though immune targeted therapies have improved outcomes in lupus nephritis, a significant number of patients experience renal damage and even progression to end stage…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].